CompletedPhase 2NCT03048474

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Netherlands Cancer Institute
Principal Investigator
Paul Baas, MD, PhD
The Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis
Intervention
nivolumab and ipilimumab(drug)
Enrollment
36 target
Eligibility
18 years · All sexes
Timeline
20162019

Study locations (1)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03048474 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma

← Back to all trials